Z Apalla, V Nikolaou, D Fattore, G Fabbrocini, A Freites-Martinez, P Sollena, M Lacouture, L Kraehenbuehl, A Stratigos, K Peris, E Lazaridou, B Richert, E Vigarios, J Riganti, B Baroudjian, A Filoni, R Dodiuk-Gad, C Lebbé, V Sibaud
The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed by the development of immune-related adverse events (irAEs). Dermatologic irAEs (dirAEs) appear in about 40% of patients undergoing immunotherapy and mainly include maculopapular, psoriasiform, lichenoid and eczematous rashes, auto-immune bullous disorders, pigmentary disorders, pruritus, oral mucosal lesions, hair and nail changes, as well as a few rare and potentially life-threatening toxicities...
March 2022: Journal of the European Academy of Dermatology and Venereology: JEADV